Pioneers of the world’s first TCR therapy

Sep. 14, 2024 • Time: 3:00 AM EDT

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer

Sep. 12, 2024 • Time: 4:05 PM EDT

Immunocore to present at the 2024 Cantor Global Healthcare Conference

Aug. 29, 2024 • Time: 7:00 AM EDT

Immunocore announces transition of Chief Financial Officer

Aug. 8, 2024 • Time: 7:00 AM EDT

Immunocore reports second quarter financial results and provides a business update

Aug. 1, 2024 • Time: 7:00 AM EDT

Immunocore to report second quarter 2024 financial results and host call on August 8, 2024

Jun. 18, 2024 • Time: 7:00 AM EDT

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma

Jun. 1, 2024 • Time: 8:00 AM EDT

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response

May. 31, 2024 • Time: 4:05 PM EDT

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

May. 30, 2024 • Time: 4:00 PM EDT

Immunocore to present at the Jefferies Global Healthcare Conference

May. 29, 2024 • Time: 7:00 AM EDT

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma